Sorafenib and its derivative SC‐49 sensitize hepatocellular carcinoma cells to CS‐1008, a humanized anti‐TNFRSF10B (DR5) antibody

Previously, we have shown that sorafenib sensitizes hepatocellular carcinoma (HCC) to apoptosis induced by TNF‐related apoptosis‐inducing ligand (TNFSF10; TRAIL). Here, we report that sorafenib and SC‐49 sensitize HCC cells to CS‐1008, a novel anti‐human death receptor 5 (TNFRSF10B) antibody.

[1]  Kuen-Feng Chen,et al.  Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. , 2011, Journal of hepatology.

[2]  Stephen P. H. Alexander,et al.  Guide to Receptors and Channels (GRAC), 5th edition , 2011, British journal of pharmacology.

[3]  Kuen-Feng Chen,et al.  Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. , 2011, European journal of medicinal chemistry.

[4]  Kuen-Feng Chen,et al.  Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3 , 2010, Clinical Cancer Research.

[5]  I. Cuthill,et al.  Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines , 2010, British journal of pharmacology.

[6]  C. Kilkenny,et al.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines , 2010, British journal of pharmacology.

[7]  Zhao-You Tang,et al.  Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.

[8]  J. Wiezorek,et al.  Death Receptor Agonists as a Targeted Therapy for Cancer , 2010, Clinical Cancer Research.

[9]  F. Sinicrope,et al.  Sorafenib Inhibits STAT3 Activation to Enhance TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells , 2010, Molecular Cancer Therapeutics.

[10]  N. Eritja,et al.  The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. , 2010, European journal of cancer.

[11]  P. Galle,et al.  TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. , 2009, World journal of gastroenterology.

[12]  G. Gores,et al.  Sorafenib inhibits signal transducer and activator of transcription‐3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2 , 2009, Hepatology.

[13]  R. Labianca,et al.  The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Hsieh,et al.  Bortezomib Overcomes Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part through the Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway* , 2009, Journal of Biological Chemistry.

[15]  B. Aggarwal,et al.  Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1 , 2009, Molecular Pharmacology.

[16]  B. Aggarwal,et al.  Boswellic Acid Blocks Signal Transducers and Activators of Transcription 3 Signaling, Proliferation, and Survival of Multiple Myeloma via the Protein Tyrosine Phosphatase SHP-1 , 2009, Molecular Cancer Research.

[17]  S. Arii,et al.  Molecularly targeted therapy for hepatocellular carcinoma , 2009, Cancer science.

[18]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[19]  R. Jove,et al.  Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas , 2008, Molecular Cancer Therapeutics.

[20]  S. Wang,et al.  The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway , 2008, Oncogene.

[21]  Mark J. Smyth,et al.  The TRAIL apoptotic pathway in cancer onset, progression and therapy , 2008, Nature Reviews Cancer.

[22]  Kuen-Feng Chen,et al.  Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. , 2008, Cancer research.

[23]  M. Yazawa,et al.  A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  J. Posey,et al.  A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas , 2008 .

[25]  W. El-Deiry,et al.  Mcl-1: a gateway to TRAIL sensitization. , 2008, Cancer research.

[26]  J A Peters,et al.  Guide to Receptors and Channels (GRAC), 3rd edition , 2008, British journal of pharmacology.

[27]  David Loegering,et al.  MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis , 2007, Journal of Biological Chemistry.

[28]  K. Eguchi,et al.  Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. , 2007, Journal of hepatology.

[29]  D. Germain,et al.  Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy , 2007, Clinical Cancer Research.

[30]  T. Curran,et al.  Deletion of Shp2 in the Brain Leads to Defective Proliferation and Differentiation in Neural Stem Cells and Early Postnatal Lethality , 2007, Molecular and Cellular Biology.

[31]  K. Flaherty,et al.  Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. , 2007, Cancer cell.

[32]  Mark A. Hall,et al.  Clearing the TRAIL for Cancer Therapy. , 2007, Cancer cell.

[33]  D. Auclair,et al.  Antitumor activity of sorafenib in FLT3-driven leukemic cells , 2007, Leukemia.

[34]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[35]  Hong Zhang,et al.  Inhibition of Growth and Metastasis of Human Hepatocellular Carcinoma by Antisense Oligonucleotide Targeting Signal Transducer and Activator of Transcription 3 , 2006, Clinical Cancer Research.

[36]  S. Wilhelm,et al.  Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2006, Nature Reviews Drug Discovery.

[37]  M. Gregor,et al.  HDAC inhibitor treatment of hepatoma cells induces both TRAIL‐independent apoptosis and restoration of sensitivity to TRAIL , 2006, Hepatology.

[38]  H. Yang-Yen Mcl-1: a highly regulated cell death and survival controller. , 2006, Journal of biomedical science.

[39]  E. Rowinsky Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  B. Fang,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in cancer , 2005, Cancer Gene Therapy.

[41]  G. Gores,et al.  Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells , 2004, Cancer Research.

[42]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[43]  K. Shiraki,et al.  Cellular FLICE/Caspase-8–Inhibitory Protein as a Principal Regulator of Cell Death and Survival in Human Hepatocellular Carcinoma , 2003, Laboratory Investigation.

[44]  I. Jeremias,et al.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB , 2003, Oncogene.

[45]  H. Yang-Yen,et al.  Interleukin-3 Stimulation of mcl-1 Gene Transcription Involves Activation of the PU.1 Transcription Factor through a p38 Mitogen-Activated Protein Kinase-Dependent Pathway , 2003, Molecular and Cellular Biology.

[46]  A. Martelli,et al.  Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation , 2003, Leukemia.

[47]  Hoguen Kim,et al.  Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin , 2002, Experimental & Molecular Medicine.

[48]  S. Fulda,et al.  Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression , 2002, Oncogene.

[49]  P. Hersey,et al.  Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. , 2001, Cancer research.

[50]  R. Ho,et al.  Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. , 2001, Cancer research.

[51]  J. Passmore,et al.  The human macrophage cell line U937 as an in vitro model for selective evaluation of mycobacterial antigen‐specific cytotoxic T‐cell function , 2001, Immunology.

[52]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[53]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[54]  Christina Falschlehner,et al.  TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. , 2009, Advances in experimental medicine and biology.

[55]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.